[go: up one dir, main page]

PE20071231A1 - Formulaciones farmaceuticas de pleconaril - Google Patents

Formulaciones farmaceuticas de pleconaril

Info

Publication number
PE20071231A1
PE20071231A1 PE2007000137A PE2007000137A PE20071231A1 PE 20071231 A1 PE20071231 A1 PE 20071231A1 PE 2007000137 A PE2007000137 A PE 2007000137A PE 2007000137 A PE2007000137 A PE 2007000137A PE 20071231 A1 PE20071231 A1 PE 20071231A1
Authority
PE
Peru
Prior art keywords
pleconaril
pharmaceutical formulations
solution
thyotrope
plecoranil
Prior art date
Application number
PE2007000137A
Other languages
English (en)
Inventor
Saeed M Chaudhry
Julianne Berry
Joel Sequeira
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38283182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071231(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20071231A1 publication Critical patent/PE20071231A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

REFERIDA A UNA SOLUCION QUE COMPRENDE PLECORANIL (1,2,4-OXADIAZOL-3-[3,5-DIMETIL-4-[3-(3-METIL-5-ISOXAZOLIL)PROPOXI]FENIL]-5-(TRIFLUORMETILO)) O UNA SAL FARMACEUTICAMENTE ACEPTABLE Y UN SOLVENTE TAL COMO HIDROFLUOROCARBONO SELECCIONADO DE 1,1,1,2,3,3,3-HEPTAFLUORPROPANO Y 1,1,1,2-TETRAFLUORETANO. LA SOLUCION PUEDE CONTENER OTROS AGENTES FARMACEUTICOS TALES COMO CORTICOESTEROIDES QUE PUEDEN SER DEXAMETASONA, MOMETASONA, BUDESONIDA, FLUTICASONA, ENTRE OTROS; DESCONGESTIONANTES QUE PUEDEN SER EFEDRINA, PSEUDOEFEDRINA, OXIMETAZOLINA, ENTRE OTROS; ANTIHISTAMINICOS QUE PUEDEN SER DESLORATADINA, LORATADINA, ASTEMIZOL, ENTRE OTRAS; ANTI-INFLAMATORIOS QUE PUEDEN SER OXITROPIO, TIOTROPIO, ENTRE OTROS; ANTIBIOTICOS; ANTI-COLINERGICOS; ENTRE OTROS. EL PLECONARIL ES UN AGENTE ANTI-VIRAL Y ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
PE2007000137A 2006-02-09 2007-02-08 Formulaciones farmaceuticas de pleconaril PE20071231A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77192106P 2006-02-09 2006-02-09

Publications (1)

Publication Number Publication Date
PE20071231A1 true PE20071231A1 (es) 2008-01-14

Family

ID=38283182

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000137A PE20071231A1 (es) 2006-02-09 2007-02-08 Formulaciones farmaceuticas de pleconaril

Country Status (9)

Country Link
US (2) US20070203104A1 (es)
EP (1) EP1981545A2 (es)
JP (1) JP2009526062A (es)
AR (1) AR059357A1 (es)
CA (1) CA2641616A1 (es)
MX (1) MX2008010353A (es)
PE (1) PE20071231A1 (es)
TW (1) TW200806291A (es)
WO (1) WO2007095039A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE503687T1 (de) * 2002-08-27 2011-04-15 Schering Corp Verfahren zur herstellung von formulierungen für inhaliergeräte mit abgemessener dosis
WO2007095043A2 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents
CN102552116B (zh) * 2010-12-24 2015-07-22 无锡济民可信山禾药业股份有限公司 一种呋麻滴鼻液的制备方法
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AU2013305569A1 (en) * 2012-08-24 2015-02-19 Vr1, Inc. Composition for the treatment of migraine headaches
US20160193188A1 (en) * 2013-08-15 2016-07-07 Antivirus Therapeutics Methods and compositions for increasing the effectiveness of antiviral agents
EP4241771A3 (en) * 2013-11-08 2023-11-22 Antivirus Therapeutics Methods and compositions for treating sepsis
DK3833665T3 (da) 2018-08-09 2023-10-09 Antabio Sas Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229070T2 (de) * 1991-02-09 1999-11-18 B.S.D. Bio Science Development Snc Di Omini C. & Zuccari G., Bussero Antireaktive antiasthmatische Wirkung von Acetylsalicylsäure durch Inhalation
ATE134509T1 (de) * 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
CA2111003A1 (en) * 1991-06-10 1992-12-23 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
US5175177A (en) * 1991-07-17 1992-12-29 Sterling Drug Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
US5349068A (en) * 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
US5453433A (en) * 1994-05-13 1995-09-26 Sterling Winthrop Inc. Thiadiazoles and antipicornaviral compositions
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
WO2003020270A1 (en) * 2001-08-29 2003-03-13 Viropharma Incorporated Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents
CA2459376A1 (en) * 2001-08-29 2003-03-13 Viropharma Incorporated Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents
RU2279292C2 (ru) * 2001-10-24 2006-07-10 Пари Гмбх Набор для приготовления фармацевтической композиции
US20060167109A1 (en) * 2002-02-14 2006-07-27 Pevear Daniel C Methods of reducing rhinovirus contagion and related compositions
DE60311665T2 (de) * 2002-08-23 2007-10-25 Schering Corp. Pharmazeutische zusammensetzungen
SG147453A1 (en) * 2003-10-20 2008-11-28 Schering Corp Pharmaceutical aerosol compositions
CA2575932A1 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
WO2007095043A2 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations

Also Published As

Publication number Publication date
JP2009526062A (ja) 2009-07-16
WO2007095039A3 (en) 2008-05-08
WO2007095039A2 (en) 2007-08-23
US20100144610A1 (en) 2010-06-10
MX2008010353A (es) 2009-03-05
CA2641616A1 (en) 2007-08-23
TW200806291A (en) 2008-02-01
AR059357A1 (es) 2008-03-26
EP1981545A2 (en) 2008-10-22
US20070203104A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
PE20071231A1 (es) Formulaciones farmaceuticas de pleconaril
PE20071250A1 (es) Formulaciones farmaceuticas que comprenden pleconaril
MX2018011278A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
BR0316082A (pt) Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit
PE20091392A1 (es) Composiciones farmaceuticas como agentes antiinflamatorios
PE20242299A1 (es) Composiciones agonistas de gip/glp1
RU2013121788A (ru) Ингибиторы репликации вич
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
TW200837074A (en) Extended triterpene derivatives
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
MA53124B1 (fr) Agents de dégradation sélectifs des récepteurs des oestrogènes
BRPI0414581B8 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR072805A1 (es) Composiciones intranasales formas galenicas y metodos de tratamiento.
AR092857A1 (es) Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
CO5140098A1 (es) Combinaciones de un agonista de betra-2 y un esteroide, su uso para tratamiento de enfermedades inflamatorias u obstructivas de las vias aereas
JP2010132695A5 (es)
ECSP077239A (es) Formulación farmacéutica
CY1112082T1 (el) Υγρη φαρμακοτεχνικη μορφη fsh
JP2014516942A5 (es)
BRPI0518282A2 (pt) uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
NO20064054L (no) Terapeutiske kombinasjoner av atypiske antipsykotika med corticotropine frigivningsfaktor antagonister

Legal Events

Date Code Title Description
FC Refusal